National Geographic USA – June 2019

IT’S TRU.

Learn more at keytruda.com

Dr. Goetz Kloecker is a

practicing oncologist and has

been compensated for his time.

Copyright © 2019 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
All rights reserved. US-LAM-00131 03/19 keytruda.com

IMPORTANT SAFETY INFORMATION
(continued)

• Rejection of a transplanted organ.People who have had

  
  

  À}>ÌÀ>ë>Ì>Þ>Ûi>VÀi>ÃiÀÃvÀ}> ÌÀ>ë>ÌÀiiVÌvÌiÞ>ÀiÌÀi>ÌiÜÌ
  9/,1 Ƃ°

  
  

  
  


• Complications, including graft-versus-host disease
  (GVHD), in people who have received a bone marrow
  (stem cell) transplant that uses donor stem cells
  (allogeneic).These complications can be severe and can
  i>Ìi>Ì°/iÃiV«V>ÌÃ>Þ>««ivÞÕ
  ÕiÀÜiÌÌÀ>ë>Ì>ÌiÌiÀLivÀiÀ>vÌiÀLi} ÌÀi>ÌiÜÌ
  9/,1 Ƃ°9ÕÀVÌÀÜÌÀÞÕvÀ ÌivÜ}Ã}Ã>ÃÞ«ÌÃ\ÃÀ>Ã]ÛiÀ
  y>>Ì]>L>«>]>`>ÀÀi>°

Getting medical treatment right away may help keep
these problems from becoming more serious.Your doctor
ÜViVÞÕvÀÌiÃi«ÀLiÃÕÀ}ÌÀi>ÌiÌÜÌ  9/,1 Ƃ°9ÕÀVÌÀ>ÞÌÀi>ÌÞÕÜÌVÀÌVÃÌiÀÀ ÀiÀi«>ViiÌiVið9ÕÀVÌÀ>Þ>Ãii
Ìi>ÞÀV«iÌiÞÃÌ«ÌÀi>ÌiÌÜÌ 9/,1 ƂvÞÕ >ÛiÃiÛiÀiÃiivviVÌð

Before you receive KEYTRUDA, tell your doctor if you have
ÕiÃÞÃÌi«ÀLiÃÃÕV>Ã
À½ÃÃi>Ãi]ÕViÀ>ÌÛi VÌÃ]ÀÕ«ÕÃÆ>Ûi>>À}>ÌÀ>ë>ÌÀ«>Ì>Ûi
or have had a bone marrow (stem cell) transplant that used
ÀÃÌiVií>}iiV®Æ>ÛiÕ}ÀLÀi>Ì} «ÀLiÃÆ>ÛiÛiÀ«ÀLiÃÆÀ>Ûi>ÞÌiÀiV>
«ÀLiðvÞÕ>Ài«Ài}>ÌÀ«>ÌLiVi«Ài}>Ì]
ÌiÞÕÀVÌÀ° 9/,1 ƂV>>ÀÞÕÀÕLÀL>LÞ°v ÞÕ>Ài>LiÌLiVi«Ài}>Ì]ÞÕÀVÌÀÜ}ÛiÞÕ>
«Ài}>VÞÌiÃÌLivÀiÞÕÃÌ>ÀÌÌÀi>ÌiÌ°1ÃiivviVÌÛiLÀÌ

VÌÀ`ÕÀ}ÌÀi>ÌiÌ>`vÀ>Ìi>ÃÌ{ÌÃ>vÌiÀÌi

w>`Ãiv

9/,1Ƃ°/iÞÕÀ`VÌÀÀ}Ì>Ü>ÞvÞÕ

ÌÞÕ>ÞLi«Ài}>ÌÀÞÕLiVi«Ài}>Ì`ÕÀ}

ÌÀi>ÌiÌÜÌ

9/,1Ƃ°

vÞÕ>ÀiLÀi>ÃÌvii`}À«>ÌLÀi>ÃÌvii`]ÌiÞÕÀ

`VÌÀ°ÌÃÌÜv

9/,1Ƃ«>ÃÃiÃÌÞÕÀLÀi>ÃÌ

°ÌLÀi>ÃÌvii``ÕÀ}ÌÀi>ÌiÌÜÌ

9/,1Ƃ

>`vÀ{ÌÃ>vÌiÀÞÕÀw>`Ãiv

9/,1Ƃ°

Tell your doctor about all the medicines you take,VÕ`}

«ÀiÃVÀ«Ì>`ÛiÀÌiVÕÌiÀi`ViÃ]ÛÌ>Ã]>`

iÀL>ÃÕ««iiÌð



Ã`iivviVÌÃv

9/,1ƂÜi}ÛiÜÌViÀÌ>

ViÌiÀ>«Þi`ViÃVÕ`i\vii}ÌÀi`ÀÜi>]

>ÕÃi>]VÃÌ«>Ì]`>ÀÀi>]`iVÀi>Ãi`>««iÌÌi]À>Ã]

ÛÌ}]VÕ}]ÌÀÕLiLÀi>Ì}]viÛiÀ]>ÀÃÃ]and

y>>ÌvÌiiÀÛiÃÌ>Ì>ÞV>ÕÃi«>]Üi>iÃÃ]

>`«>À>ÞÃÃÌi>ÀÃ>`i}ð

/iÃi>ÀiÌ>Ìi«ÃÃLiÃ`iivviVÌÃv

9/,1Ƃ°

/iÞÕÀ`VÌÀvÞÕ>Ûi>ÞÃ`iivviVÌÌ>ÌLÌiÀÃ

ÞÕÀÌ>Ì`iÃÌ}>Ü>Þ°ÀÀivÀ>Ì]>Ã

ÞÕÀ`VÌÀÀ«>À>VÃÌ°

Please read the adjacent Important Information About

KEYTRUDA and discuss it with your oncologist.

You are encouraged to report negative side effects of

prescription drugs to the FDA. Visit http://www.fda.gov/medwatch

or call 1-800-FDA-1088.

>Û}ÌÀÕLi«>Þ}vÀÞÕÀiÀVi`Vi¶

Merck may be able to help.

http://www.merckhelps.com

The immunotherapy with the most FDA-approved uses for advanced lung cancer

Half of the patients receiving KEYTRUDA with chemotherapy were alive without their cancer spreading, growing, or getting

worse at 8.8 months compared with 4.9 months for patients receiving chemotherapy alone. Cancer did not progress in 40%

of patients receiving KEYTRUDA with chemotherapy compared with 19% of patients receiving chemotherapy alone.